


AMENDMENT TRANSMITTAL LETTER (Small Entity)			Docket No. 1373.016		
Applicant(s): Rutenberg, et al.					
Serial No. 09/922,013	Filing Date August 3, 2001	Examiner W. H. Beisner	Group Art Unit 1623		
Invention: DETECTION OF EPITHELIAL DYSPLASIA					
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
<input checked="" type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.					
<input type="checkbox"/> A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	24 -	26 =	0 x	\$9.00	\$0.00
INDEP. CLAIMS	5 -	5 =	0 x	\$42.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 02-2105 A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.					
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
Dated: December 11, 2002					
<div style="display: flex; justify-content: space-between;"><div style="width: 45%;"><p style="text-align: center;"><i>Signature</i></p><p>Peter L. Berger, Esq. Reg. No. 24,570 Levisohn, Lerner, Berger & Langsam, LLP 757 Third Avenue, Suite 2500 New York, New York 10017 Phone (212) 486-7272 Fax (212) 486-0323</p></div><div style="width: 50%; border: 1px solid black; padding: 5px;"><p>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</p><p style="text-align: center;">_____ <i>Signature of Person Mailing Correspondence</i></p><p style="text-align: center;">_____ <i>Typed or Printed Name of Person Mailing Correspondence</i></p></div></div>					
cc:					

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			Docket No. 1373.016
Applicant(s): Rutenberg, et al.			
Serial No. 09/922,013	Filing Date August 3, 2001	Examiner W. H. Beisner	Group Art Unit 1623
Invention: DETECTION OF EPITHELIAL DYSPLASIA			
FAX RECEIVED DEC 12 2002 GROUP 1600			
I hereby certify that this <u>Amendment transmittal, Amendment, Petition for Extension and proposed drawings</u> (Identify type of correspondence)			
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-308-4242</u>)			
on <u>December 11, 2002</u> (Date)			
<u>Wanda Ruggiera</u> (Typed or Printed Name of Person Signing Certificate)			
<u></u> (Signature)			
Note: Each paper must have its own certificate of mailing.			

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application: Rutenberg, et al
Serial No.: 09/922,013
Filed: August 3, 2001
Art Unit: 1623
Examiner: W. H. Beisner
For: DETECTION OF EPITHELIAL DYSPLASIA

Docket No. 1373.016

December 11, 2002

Don't
12/16/02
WB

VIA FAX (703) 308-4242

Hon. Commissioner of Patents & Trademarks
Washington, D. C. 20231

AMENDMENT

Sir:

In response to the Official Action of July 30, 2002, please consider the following amendment.

IN THE SPECIFICATION:

Beginning on the bottom of page 5 and continuing on the top of page 6, please replace the description of the drawings as follows:

Brief Description of the Drawings:

Fig. 1 is a cell image of an example of atypical cells.

Fig. 2 is another cell image of an example of atypical cells.

Fig. 3 is a cell image of cells which are positive for dysplasia or carcinoma.

Fig. 4 is a flowchart of a method in accordance with one embodiment of the present invention which utilizes biomarker in the process of identifying cancerous and precancerous cells.

Fig. 5 is a flowchart of a method in accordance with another embodiment of the invention which utilizes a DNA ploidy analysis in the process of identifying cancerous and precancerous cells.

Fig. 6 is a flowchart of a method in accordance with the preferred embodiment of the invention which utilizes both biomarkers and a DNA ploidy analysis in the process of identifying cancerous and precancerous cells.